Capriotti's (CAPR) has FDA BLA approval coming tomorrow with 15.5M short shares trapped, creating potential for a significant short squeeze and stock price surge. Key risks include regulatory delays, FDA rejection, and the possibility that short sellers exit positions before the catalyst rather than getting squeezed.